NVL-655
- Generic Name
- NVL-655
- Drug Type
- Small Molecule
- Background
NVL-655 is an orally bioavailable, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor inhibitor being investigated for the treatment of non-small cell lung cancer.
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC
- Conditions
- Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06834074
- Locations
- 🇨ðŸ‡
Kantonsspital Luzern, Lucerne, Switzerland
🇫🇷GCS IUCT Oncopole, Toulouse, Occitanie, France
🇫🇷Institut Gustave Roussy, Villejuif, Île-de-France, France
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1
Recruiting
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT05384626
- Locations
- 🇩🇪
Universitatsklinikum Koln - University Hospital Cologne, Cologne, Germany
🇩🇪Universkitatsklinikum Heidelberg - University Hospital Heidelberg, Heidelberg, Germany
🇯🇵Okayama University Hospital, Okayama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath